OverviewStudy detailsEligibilityThings to knowResearchStudy plan
info
Simplify with AI

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

PHASE2RECRUITING

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.

Study details:

This study will evaluate the safety and efficacy of zipalertinib in participants with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations or other uncommon/single or compound Epidermal Growth Factor Receptor Proteins Mutations (EGFRmts). Additionally, drug-drug interaction (DDI) substudy will assess the potential DDI effects of zipalertinib on the pharmacokinetics (PK) of cytochrome P450 (CYP) enzyme substrates and transporter substrates and also evaluate the relationship between zipalertinib concentration and QT interval change from baseline. Participants will be enrolled into 1 of the 4 following cohorts:.

* Cohort A ("prior ex20ins treatment") will include participants harboring EGFR ex20ins who have progressed on or after initial treatment with standard platinum-based chemotherapy and prior treatment with an ex20ins agent for their advanced disease (administered together or separately). * Cohort B ("first-line") will include participants harboring EGFR ex20ins who have not received prior treatment for advanced or metastatic disease and are not appropriate candidates for first-line doublet platinum-based chemotherapy or have refused first-line doublet platinum-based chemotherapy. * Cohort C ("active brain mets") will include participants harboring EGFR ex20ins or other uncommon single or compound EGFRmts and active brain metastases and/or leptomeningeal disease (LMD).

Participants may or may not have had prior treatment for advanced disease. * Cohort D ("other uncommon EGFRmts") will include participants harboring other non-ex20ins, excluding C797S (uncommon single or compound) EGFRmts who have not received prior systemic therapy for their locally advanced or metastatic NSCLC disease. For DDI substudy, participants will be enrolled in two groups:.

* CYP Cocktail Group will receive a single dose of cocktail of CYP enzyme probe substrates (CYP cocktail) alone prior to the start of zipalertinib dosing and a single dose of CYP cocktail in combination with zipalertinib at steady state. * Transporter Cocktail Group will receive a single dose of transporter probe substrates (Transporter cocktail) alone prior to the start of zipalertinib dosing and a single dose of Transporter cocktail in combination with zipalertinib at steady state.

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  1. Written informed consent.
  2. ≥18 years of age (or meets the country's regulatory definition of legal adult age, whichever is greater.
  3. Pathologically confirmed, locally advanced or metastatic NSCLC meeting all the following criteria.
  4. Cohort A participants: Documented EGFR ex20ins status, as determined by local testing performed at a Clinical Laboratory Improvement Amendments (CLIA) certified (United States [US]) or locally certified laboratory (outside the US). Progressed on or after systemic therapy with an agent targeting ex20ins, either alone or in combination with standard platinum-based chemotherapy for the treatment of advanced disease. Participants who discontinued previous treatment due to unacceptable toxicity are eligible.
  5. Cohort B participants: Documented EGFR ex20instatus, as determined by local testing performed at a CLIA-certified (US) or locally certified laboratory (outside the US). Participants who have not received prior treatment for advanced or metastatic disease and who are not appropriate candidates for first-line doublet platinum-based chemotherapy based on Investigator judgment or has refused first-line doublet platinum-based chemotherapy following discussion with the Investigator. Prior adjuvant/neoadjuvant treatment for early-stage disease must have been completed >6 months prior to the first dose of study treatment.
  6. Cohort C participants: Documented ex20ins or other uncommon single or compound EGFR non-ex20ins status, as determined by local testing performed at a CLIA-certified (US) or locally certified laboratory (outside the US). Presence of brain metastasis(es) characterized as at least one of the following: Newly diagnosed and/or progressive brain metastasis(es) measurable by Response Assessment in Neuro-oncology Brain Metastases (RANO-BM) criteria and not subjected to CNS-directed therapy, AND/OR LMD measurable or non-measurable by RANO-BM criteria and confirmed by a positive cerebrospinal fluid cytology, or unequivocal radiographic and/or clinical determination. Participants may not require other immediate CNS-directed therapy or will likely require other CNS directed anti-tumor therapy during the first cycle of study treatment, as judged by the Investigator.
  7. Cohort D participants: Documented other uncommon single or compound EGFR non-ex20ins status (excluding C797S), as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US). A list of eligible mutations will be provided in a separate document. Participants with brain metastasis must be neurologically stable. Participants must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS- directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the Screening Period, and they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Participants with history of uncontrolled seizures or LMD are not eligible. Participants who have not received prior systemic therapy for their locally advanced or metastatic NSCLC disease. Prior adjuvant/neoadjuvant treatment for early-stage disease must have been completed >6 months prior to the first dose of study treatment. Participants may not have received prior adjuvant/neoadjuvant treatment with any EGFR tyrosine kinase inhibitor (TKI).
  8. Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
  9. Archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFRmt status and, where possible, other biomarkers (details provided in a laboratory manual). Participants with insufficient tissue may be eligible following discussion with the Sponsor.
  10. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1.
  11. Adequate organ function, as defined by the hematologic, renal and hepatic laboratory values.
  12. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test prior to administration of the first dose of study treatment. Female participants are not considered to be of childbearing potential if they are post-menopausal (no menses for 12 months without an alternative medical cause) or permanently sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).
  13. Both males and females of reproductive potential must agree to use effective birth control during the study prior to the first dose of study drug and for 1 month after the last dose of study treatment.

Exclusion criteria

  1. Participant is currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged to be scientifically or medically incompatible with this study.
  2. Has received any of the following within the specific time frame specified: Participant has received Zipalertinib (TAS6417/CLN081) at any time. Thoracic radiotherapy ≤28 days or palliative radiation (gamma knife radiotherapy is allowed) ≤14 days prior to the first dose of study treatment. Anticancer immunotherapy ≤28 days prior to the first dose of study treatment. Major surgery (excluding placement of vascular access) ≤28 days prior to the first dose of study treatment. All prescribed medication, over-the-counter medication, vitamin preparations and other food supplements, or herbal medications that are strong or moderate CYP3A4 inducers or inhibitors within 7 days prior to first dose of study treatment.
  3. Have any unresolved toxicity of Grade ≥2 from previous anticancer treatment, except for Grade 2 alopecia or skin pigmentation. Participants with other chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the Investigator and Sponsor.
  4. Past medical history of interstitial lung disease, treatment-related pneumonitis (any grade), or evidence of clinically active interstitial lung disease.
  5. Impaired cardiac function or clinically significant cardiac disease including any of the following: History of congestive heart failure (CHF) Class III/IV according to the New York Heart Association (NYHA) Functional Classification. Serious cardiac arrhythmias requiring treatment. Resting corrected QT interval (QTc) >470 msec using Fridericia's formula (QTcF).
  6. Is unable to swallow tablets or has any disease or condition that may significantly affect gastrointestinal absorption of zipalertinib (eg, inflammatory bowel disease, malabsorption syndrome, or prior gastric/bowel resection).
  7. History of another primary malignancy ≤2 years prior to the date of first dose of study treatment unless at least one of the following criteria are met: Adequately treated basal or squamous cell carcinoma of the skin, Cancer of the breast or cervix in situ, Participants with previously treated malignancy if all treatment for that malignancy was completed at least 2 years prior to first dose and no evidence of disease, Participants with concurrent malignancy clinically stable and not requiring tumor-directed treatment.
  8. Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) that is not controlled with treatment.
  9. History of Coronavirus disease 2019 (COVID-19) infection within 4 weeks prior to enrollment and/or has persistent clinically significant pulmonary symptoms related to prior COVID-19 infection.
  10. Active bleeding disorders.
  11. Known hypersensitivity to the ingredients in zipalertinib or any drugs similar in structure or class.
  12. Is pregnant, lactating, or planning to become pregnant.
  13. The participant is, in the Investigator's opinion, unable or unwilling to comply with the trial procedures.
  14. Any other clinically significant acute or chronic medical or psychiatric condition that may increase the risk associated with study drug administration, or may interfere with the interpretation of substudy results based on Investigator discretion.

Eligibility

Age eligible for study : NA

Healthy volunteers accepted : No

Gender eligible for study: ALL

Things to know

Study dates

Study start:

Primary completion:

Study completion finish:

study type

Study type

TREATMENT

phase

Phase

    PHASE2

trial

Study ID

NCT05967689

Intervention or treatment

DRUG: TAS6417

DRUG: CYP Cocktail

DRUG: Transporter Cocktail

Conditions

  • Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

  • Condition: Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

  • DRUG: TAS6417 and other drugs

  • Bankstown, New South Wales, Australia and more

  • Sponsor: Taiho Oncology, Inc.

Save

Share

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial?

If you're a clinic or sponsor, you can claim this study

Research sites nearby

Closest Location:

Bankstown-Lidcombe Hospital

Select from list below to view details:

  • Bankstown-Lidcombe Hospital

    Bankstown, New South Wales, Australia

  • Genesis Care North Shore

    Saint Leonards, New South Wales, Australia

  • Joondalup Hospital Pharmacy

    Joondalup, Western Australia, Australia

Loading map...

Who is running the clinical trial?

TOI

Taiho Oncology, Inc.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: Cohort A ("prior ex20ins treatment")
  • Cohort A ("prior ex20ins treatment") participants will receive zipalertinib orally twice a day (BID) continuously until documentation of progressive disease (PD) or until other withdrawal criteria are met, whichever comes first.
Drug: TAS6417
    EXPERIMENTAL: Cohort B ("first-line treatment")
    • Cohort B participants will receive zipalertinib orally, BID continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.
    Drug: TAS6417
      EXPERIMENTAL: Cohort C ("active brain mets")
      • Cohort C participants will receive zipalertinib orally, BID continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.
      Drug: TAS6417
        EXPERIMENTAL: Cohort D ("other uncommon EGFRmts").
        • Cohort D participants will receive zipalertinib orally, BID continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.
        Drug: TAS6417
          EXPERIMENTAL: DDI Substudy: CYP Cocktail Group
          • Participants will receive a single dose of CYP enzyme probe substrates (CYP cocktail) alone prior to the start of zipalertinib dosing and a single dose of CYP cocktail in combination with zipalertinib at steady state. Zipalertinib will be dosed, orally BID in Cycle 1 (cycle length = 21 days), followed by continuous treatment with zipalertinib until documentation of PD or until other withdrawal criteria are met, whichever comes first.
          Drug: TAS6417, Drug: CYP Cocktail
            EXPERIMENTAL: DDI Substudy: Transporter Cocktail Group
            • Participants will receive a single dose of transporter probe substrates (Transporter cocktail) alone prior to the start of zipalertinib dosing and a single dose of Transporter cocktail in combination with zipalertinib at steady state. Zipalertinib will be dosed, orally BID in Cycle 1 (cycle length = 21 days), followed by continuous treatment with zipalertinib until documentation of PD or until other withdrawal criteria are met, whichever comes first.
            Drug: TAS6417, Drug: Transporter Cocktail
              EXPERIMENTAL: Dose Optimization Substudy: Arm A
              • Participants will receive zipalertinib, orally, at Arm A dose, BID, continuously in 21-day treatment cycles until the participant meets any of the treatment discontinuation criteria.
              Drug: TAS6417
                EXPERIMENTAL: Dose Optimization Substudy: Arm B
                • Participants will receive zipalertinib, orally, at Arm B dose, BID, continuously in 21-day treatment cycles until the participant meets any of the treatment discontinuation criteria.
                Drug: TAS6417

                  What is the study measuring?

                  Primary Outcome

                  MeasureDescriptionTime Frame
                  Cohorts 1-4: Objective Response Rate (ORR)Not SpecifiedUp to approximately 2 years

                  Secondary Outcome

                  MeasureDescriptionTime Frame
                  Cohorts 1-4: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0)Not SpecifiedUp to approximately 2 years
                  Cohorts 1-4: Number of Participants with Clinically Significant Changes in Clinical Laboratory ParametersNot SpecifiedUp to approximately 2 years
                  Cohorts 1-4: Number of Participants with Clinically Significant Changes in Vital SignsNot SpecifiedUp to approximately 2 years
                  Cohorts 1-4: Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) ParametersNot SpecifiedUp to approximately 2 years
                  Cohorts 1-4: Number of participants With Change in Left Ventricular Ejection Fraction (LVEF) Evaluated Using Electrocardiography (ECHO) and Multigated Acquisition (MUGA) ScanNot SpecifiedUp to approximately 2 years
                  Cohorts 1-4: Disease Control Rate (DCR)Not SpecifiedUp to approximately 2 years
                  Cohorts 1-4: Duration of Response (DoR)Not SpecifiedUp to approximately 2 years
                  Cohorts 1-4: Progression-free Survival (PFS)Not SpecifiedUp to approximately 2 years
                  Cohorts 1-4: Overall Survival (OS)Not SpecifiedUp to approximately 2 years
                  Cohort C: Intracranial (i) Overall Response Rate (iORR)Not SpecifiedUp to approximately 2 years
                  Cohort C: Intracranial Duration of Complete Response (iDCR)Not SpecifiedUp to approximately 2 years
                  Cohort C: Intracranial Duration of Response (iDoR)Not SpecifiedUp to approximately 2 years
                  Cohorts 1-4: Minimum Plasma Concentration (Cmin) of ZipalertinibNot SpecifiedUp to approximately 2 years
                  DDI Substudy: Change From Baseline in QT interval Corrected for Heart Rate using Fridericia's formula (QTcF) Interval Following Zipalertinib Administration in CYP Cocktail GroupNot SpecifiedCycle 1 (cycle length = 21 days)
                  DDI Substudy: Geometric Mean Maximum Plasma Concentration (Cmax) After Multiple Dose Administration of Zipalertinib in CYP Group and Transporter Cocktail GroupsNot SpecifiedCycle 1 (cycle length = 21 days)
                  DDI Substudy: Geometric Mean Area Under Curve (AUC) After Multiple Dose Administration of Zipalertinib in CYP Group and Transporter Cocktail GroupsNot SpecifiedCycle 1 (cycle length = 21 days)
                  DDI Substudy: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) in CYP Group and Transporter CocktailNot SpecifiedCycle 1 (cycle length = 21 days)
                  Are you running this trial?If you're a clinic or sponsor, you can claim this study.
                  Claim this trial

                  References

                  Clinical Trials Gov: A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

                  Other trials to consider

                  Loading suggested trials...

                  Top searched conditions

                  Breast CancerLung CancerType 2 DiabetesDermatitisAlzheimersParkinsonsLupusCrohn’s DiseaseAsthmaHypertensionCOPDMultiple SclerosisOsteoarthritisHIV/AIDSPsoriasisStrokeObesityProstate CancerDepressionCardiovascular